Nabota is manufactured by Daewoong Pharmaceutical, a leading South Korean pharmaceutical company headquartered in Seoul. The company developed this botulinum toxin type A product and successfully brought it to market through extensive research and development spanning several years.
About Daewoong Pharmaceutical Co., Ltd.
Daewoong Pharmaceutical was established in 1934 and has grown into one of Korea’s most prominent pharmaceutical companies. The company specializes in developing innovative biopharmaceutical products and has invested heavily in advanced manufacturing facilities and research capabilities. Daewoong’s biopharmaceutical division focuses onBotulinum toxin products, recombinant proteins, and other biological medicines.
“Daewoong Pharmaceutical has established itself as a trusted name in the pharmaceutical industry with over 80 years of experience in drug development and manufacturing.”
The company operates multiple manufacturing facilities that comply with international pharmaceutical standards including GMP (Good Manufacturing Practice) certifications. Their commitment to quality control and continuous improvement has enabled them to serve markets across Asia, Europe, and North America.
Nabota Product Specifications
Nabota is a purified botulinum toxin type A complex that is used for both therapeutic and aesthetic applications. The product undergoes rigorous purification processes to ensure safety and efficacy.
| Specification | Details |
|---|---|
| Active Ingredient | Botulinum Toxin Type A |
| Form | Lyophilized powder for injection |
| Strength | 100 units per vial |
| Storage | 2-8°C (refrigerated) |
| Shelf Life | 36 months from manufacturing date |
Manufacturing Process and Quality Assurance
Daewoong Pharmaceutical implements a comprehensive quality management system throughout the entire manufacturing process of Nabota. The production involves several critical stages:
- Fermentation: Controlled bacterial fermentation to produce botulinum toxin complexes
- Purification: Multi-step purification processes to isolate the active toxin component
- Formulation: Precise formulation with excipients to ensure stability
- Lyophilization: Freeze-drying process to create stable powder form
- Quality Testing: Comprehensive testing for potency, purity, and safety
- Packaging: Aseptic filling into sterile vials under controlled conditions
Each batch undergoes extensive quality control testing including:
- Potency assay to verify biological activity
- Sterility testing for microbial contamination
- Endotoxin testing to ensure patient safety
- Stability testing under various storage conditions
- Identity verification through multiple analytical methods
Regulatory Approvals and Market Presence
Nabota has received regulatory approvals in multiple countries, making it available to healthcare providers and patients worldwide. The product’s approval history demonstrates Daewoong’s commitment to meeting international regulatory standards.
| Region/Country | Approval Year | Regulatory Body |
|---|---|---|
| South Korea | 2014 | Ministry of Food and Drug Safety (MFDS) |
| United States (FDA) | 2019 | Food and Drug Administration |
| European Union | 2021 | European Medicines Agency (EMA) |
| Japan | 2020 | Pharmaceuticals and Medical Devices Agency (PMDA) |
FDA Approval Details
The U.S. FDA approval in 2019 was a significant milestone for Daewoong Pharmaceutical. Nabota became the first Korean botulinum toxin product to receive FDA approval for cosmetic use, specifically for the temporary improvement of glabellar lines (frown lines between the eyebrows). The approval was based on clinical trial data demonstrating both safety and efficacy in the target patient population.
Global Distribution Network
Daewoong has established partnerships with international distributors to ensure reliable supply of Nabota to markets around the world. The distribution network covers:
- North America (United States, Canada)
- Europe (Germany, France, United Kingdom, Italy, Spain)
- Asia-Pacific (South Korea, Japan, China, Australia, Southeast Asia)
- Latin America (Brazil, Mexico, Argentina)
- Middle East and Africa
If you are interested in purchasing Nabota for professional medical or aesthetic use, you can buy nabota from authorized distributors.
Competitive Position in Botulinum Toxin Market
Nabota competes with several established botulinum toxin brands in the global market. Understanding its position helps healthcare providers make informed decisions.
| Product | Manufacturer | Origin | Market Segment |
|---|---|---|---|
| Nabota | Daewoong Pharmaceutical | South Korea | Premium/Professional |
| Botox | Allergan (AbbVie) | United States | Premium/Luxury |
| Dysport | Ipsen | France/UK | Mid-Premium |
| Xeomin | Merz Pharmaceuticals | Germany | Professional |
| Jeuveau | Evolus | South Korea | Competitive |
Manufacturing Technology and Innovation
Daewoong Pharmaceutical has invested significantly in developing proprietary manufacturing technologies for Nabota. The company utilizes advanced fermentation and purification methods that maintain high quality standards while optimizing production efficiency. Their facilities incorporate state-of-the-art equipment including:
- Closed bioreactor systems for contamination control
- Multi-stage filtration systems for purity
- Advanced lyophilization technology for stability
- Automated inspection and packaging lines
The manufacturing technology enables consistent product quality across batches, which is critical for botulinum toxin products where potency accuracy directly impacts clinical outcomes.
Clinical Data and Efficacy
Clinical trials for Nabota have demonstrated its effectiveness in both therapeutic and aesthetic applications. The FDA approval was supported by two pivotal phase 3 clinical trials involving over 1,000 patients. Key findings included:
- Onset of action: Visible improvement typically observed within 3-5 days
- Duration of effect: Average duration of 4-6 months depending on treatment area
- Patient satisfaction: High rates of satisfaction reported in clinical follow-up surveys
- Safety profile: Adverse events generally mild and temporary in nature
Research and Development Investment
Daewoong Pharmaceutical allocates substantial resources to research and development for their botulinum toxin products. Their R&D initiatives include:
- Process optimization to improve manufacturing efficiency and consistency
- New formulation development to enhance product stability
- Comparative studies with other botulinum toxin products
- Long-term safety monitoring programs
- Development of additional therapeutic indications
The company’s R&D facilities are staffed with experienced scientists and researchers who continue to advance Nabota’s technology platform.
Supply Chain and Distribution Transparency
Ensuring product integrity throughout the supply chain is a priority for Daewoong. The company has implemented track-and-trace systems to monitor Nabota from manufacturing to end-user delivery. This includes:
- Serialization of individual product units
- Temperature monitoring during transportation
- Verification systems to prevent counterfeit products
- Direct relationships with authorized distributors
Manufacturing Capacity and Future Outlook
Daewoong Pharmaceutical has expanded manufacturing capacity to meet growing global demand for Nabota. Their production facilities are designed to scale operations while maintaining quality standards. The company’s strategic plan includes:
Continued investment in manufacturing infrastructure and technology to support expanding market presence across multiple regions while maintaining the highest quality standards required by international regulatory authorities.
The manufacturing capabilities allow Daewoong to serve both established markets and expand into emerging markets where demand for botulinum toxin products continues to grow.
Quality Certifications and Compliance
Daewoong maintains multiple international certifications for their manufacturing operations. These certifications demonstrate compliance with stringent regulatory requirements across different markets.
| Certification | Standard | Scope |
|---|---|---|
| Korean GMP | KGMP | Domestic compliance |
| US FDA | cGMP | US market authorization |
| EU GMP | EUGMP Annex | European market access |
| ISO 9001 | Quality Management | General quality systems |
| ISO 14001 | Environmental Management | Environmental compliance |
Medical and Aesthetic Applications
Nabota is indicated for various therapeutic and cosmetic applications. Healthcare providers use this product for treating conditions including:
- Cosmetic: Temporary improvement of moderate to severe glabellar lines, crow’s feet, and forehead wrinkles
- Therapeutic: Treatment of cervical dystonia, blepharospasm, and upper limb spasticity
- Off-label: Various other muscle hyperactivity conditions as determined by healthcare professionals
The versatility of Nabota in both aesthetics and therapeutics demonstrates the comprehensive approach Daewoong has taken in developing their botulinum toxin portfolio.
Healthcare Provider Support
Daewoong provides extensive support to healthcare providers using Nabota, including training programs, educational materials, and technical support. The company offers:
- Injection technique training workshops
- Product handling and storage guidance
- Clinical support resources
- Patient education materials
- 24/7 medical information services
This support infrastructure helps ensure safe and effective use of Nabota across different healthcare settings.
Market Performance and Recognition
Nabota has gained significant market share in various regions since its introduction. The product’s combination of quality, efficacy, and competitive pricing has resonated with healthcare providers and patients alike. Market analysis indicates consistent growth in both prescription volumes and geographic expansion.